HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

Hepatocellular carcinoma (HCC), the most common liver malignancy with a poor prognosis and increasing incidence, remains a serious health problem worldwide. Immunotherapy has been described as one of the ideal ways to treat HCC and is transforming patient management. However, the occurrence of immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Chen, Li, Mei, Duan, Yujuan, Jiang, Xin, Hou, Xiaoming, Xue, Fulai, Zhang, Yinan, Luo, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250615/
https://www.ncbi.nlm.nih.gov/pubmed/37304265
http://dx.doi.org/10.3389/fimmu.2023.1170207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250615/
https://www.ncbi.nlm.nih.gov/pubmed/37304265
http://dx.doi.org/10.3389/fimmu.2023.1170207

Ejemplares similares